TTif Hi«pn«irinn and rliminarinn nf phgrmpgriding wm «niHiifl in fiv* normal nihjecfs, and in %ix patient* whh hepatic disease. Plasma concentrations of phenoperidine were generally higher in patients with hepatic dysfunction. Secondary peaks were observed between 15 and 105 min (particularly in patients with liver disease). In the patients the terminal half-life of phenoperidine was prolonged by approximately 50%, mainly because of a decrease in the clearance of the drug. There was little or no change in the total apparent volume of distribution. However, the differences between normal subjects and patients with hepatic disease were not statistically significant. The results suggest that slight or moderate impairment of hepatic function does not significantly affect the kinetics of the drug, and that modification of its dosage may not be required.
Although phenylpiperidine analgesics are extensively metabolized by the liver, the effects of hepatic disease on their disposition and elimination are extremely variable. The kinetics of pethidine are considerably modified in patients with hepatic disease; in cirrhosis, its half-life is prolonged from 3.2 to 7.0 h as a result of a decrease in plasma clearance (Klotz et al., 1974) . In contrast, the terminal halflife of fentanyl is prolonged only slightly in patients with cirrhosis, and there is little or no change in its plasma clearance or volume of distribution (Haberer et al., 1982) . The effect of liver disease on the kinetics of related analgesics is less clearly defined. In the present study, the distribution and elimination of phenoperidine have been compared in healthy volunteer subjects, and in patients with hepatic dysfunction who were investigated by liver biopsy.
SUBJECTS, PATIENTS AND METHODS
Studies were carried out in five healthy male volunteer subjects (body weights 55-90kg), and in six patients with hepatic dysfunction (body weights 44-83 kg; four male). The age range of the control subjects (22-47yr) was slightly less than the patients with liver disease (30-61 yr). Two of the patients were taking other drugs concurrently: one received penicilLaminc 500 mg day" 1 , and the other 1 . In all the patients studied, phenoperidine was administered during the course of liver biopsy. Both the volunteers and the patients gave their informed consent to the procedure, and assessment of renal and hepatic function was carried out before each investigation.
All studies were carried out with the volunteers and patients in the supine position. After the injection of phenoperidine hydrochloride lO^gkg" 1 , i. v., blood samples (usually 8 ml) were removed at 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90 ,105 and 120 min. All blood samples were placed in tubes containing lithium heparin, and plasma was removed as soon as possible by centrifugation. Urine was collected from volunteers and patients for 24 h and stored at -20 °C. No attempt was made to control or modify the pH of the urine. The concentration of phenoperidine, in plasma and urine, was measured by gas-liquid chromatography, using a nitrogen detector (Chan et al., 1981) .
RESULTS
All the volunteer subjects had normal renal and hepatic function (as assessed by clinical or biochemical criteria). In contrast, in five of the six patients liver function tests were abnormal (table I) . The results of liver biopsy were extremely variable; one patient had primary binary cirrhosis with positive antimitochondrial antibodies, three had histological changes that were considered to be related to alcohol abuse, while the remaining two patients had hepatitis of uncertain aetiology (table I) . Nevertheless, all of the patients had only slight impairment of hepatic functional reserve, according to the classification of Child (1964) .
Although the decline in the plasma concentration of phenoperidine was similar in both groups, the values were generally greater in patients with hepatic disease ( fig. 1 ). The initial plasma concentration of phenoperidine in patients with hepatic disease was more than twice the value obtained in the normal subjects. In both groups, secondary increases in plasma concentration were observed 15-105 min after the injection of the phenoperidine i.v. These secondary peaks were more evident in patients with liver disease than in the normal subjects ( fig. 1 ).
The plasma half-life of phenoperidine (Tj s ) in normal volunteers and patients was calculated from the terminal decline in concentration by least squares regression analysis (omitting any data points associated with secondary peaks). Clearance of phenoperidine was derived from the expression Ch = dose/AUCo-».i2o> and the apparent volume of distribution from the equation V= (Cip x Tfifln 2. In normal subjects, the plasma half-life, clearance, and apparent volume of distribution of phenoperidine were generally similar to the values obtained previously in anaesthetized patients with normal renal and hepatic function (Milne et al., 1980) . Differences were observed in patients with hepatic disease (table II) . The plasma half-life of phenoperidine was prolonged from 61 ±8 min to 92 ± 18 min (mean ± SEM), mainly as a result of a decrease in plasma clearance from 26±4mlmin" 1 kg-1 to lyiamlmin-'kg" 1 (mean ± SEM). The apparent volume of distribution was relatively constant ( 
2.1±0.4
biochemical tests of liver dysfunction and the prolonged half-life or decreased clearance of phenoperidine. In individual patients, serum concentrations of aspartate aminotransferase (table I) were most closely related to decreases in clearance (table II) . The patient with the longest plasma halflife (174 min) had primary biliary cirrhosis and the highest serum concentration of y-glutamyl transpeptidase (table I) . The proportion of the dose of phenoperidine eliminated unchanged in urine was increased in patients with hepatic disease (from 2.3 ±0.4% to 7.8 ±0.8%). Correspondingly, the elimination of norpethidine and pethidine (the mnin metabolites of phenoperidine) was decreased (table III), so the total proportion of the dose eliminated in urine was substantially unchanged.
DISCUSSION
In this study, the plasma concentration of phenoperidine was greater in patients with hepatic dysfunction than in normal subjects. Secondary peaks in the plasma concentration were usually present between 15 and 105 min (particularly in patients with liver disease). Similar peaks were also observed when other narcotic analgesics (e.g. fentanyl) were used during anaesthesia (McQuay et al., 1979; Stoeckel, Hengstmann and Schuttler, 1979) . It has been suggested that these secondary peaks may be partly attributable to the diffusion of the drug from plasma to the stomach, followed by its subsequent reabsorption from the small intestine; some of the reabsorbed drug may escape presystemic metabolism, causing secondary peaks in the plasma concentration (Stoeckel, Hengstmann and Schuttler, 1979; Calvey et al., 1983) . In liver disease, the proportion of the reabsorbed drug that escapes pre-systemic elimination may be increased, as a result of a decrease in hepatic blood flow or enzyme activity. Consequently, the plasma concentrations of phenoperidine associated with the secondary peaks are increased. Since the recurrent respiratory depression sometimes observed after the administration of other narcotic analgesics may be related to the presence of similar peaks (Becker et al., 1976; Adams and Pybus, 1978) , this phenomenon may be of some practical importance. In both the normal subjects and the patients with hepatic disease, accurate determination of the terminal half-life of phenoperidine was complicated by the presence of these secondary peaks. Data points associated with the peaks were not used in calculations of the half-life. In addition, there was marked inter-individual variation in the plasma concentration of phenoperidine in both the normal subjects and the patients with hepatic disease. In patients with liver disease, the terminal half-life of phenoperidine was prolonged by approximately 50%, mainly because of a decrease in the clearance of the drug. There was little change in the total apparent volume of distribution. Differences between normal subjects and patients with hepatic disease were not statistically significant. Nevertheless, the influence of liver disease on the clearance and halflife of phenoperidine is generally similar to its effects on the elimination of pethidine (Klotz et al., 1974) . The clearance of both narcotic analgesics by the liver Sc estudi6 la disposicion y la eliminacion de la fenoperidina en cinco tujetos normalei y en seis pacientes con enfermedades hepatkas. Las concentraciones de fenoperidina en el plasma eran en general mayorei en lot pacicmct con ftisfiinrtfm hepatica. Se observaron picas tecundarios entre lot lSy 105min(en particular en los pacientes con enfennedadcs hepaticas). F? n los pacientes, la media-vida terminal de la fenoperidina te prolongo en un 50% npm* irnQHom^nti^ principalmente en base a la disminnrion de la eliminacion de la substancia. Pocos cambios o ningiin cambio se observaron en el vohimen total aparentc de distribudon. Sin embargo, las diferencias entre los sujetos normalw ct los pacicntes con ^nf^nTy^y^^f hepatlcat no fueron tignificantes drtdf el punto de vista estadistico. Los resultados sugieren que un pequefio deterioro o ""» moderado en la fiinriiSn hepatica no afectan de manera signi£cativa la cin^TkT! de la substancia y que no cs necesario T f) tv^*^ror las dotis. Downloaded from https://academic.oup.com/bja/article-abstract/56/8/843/240959 by guest on 28 December 2018
